Active Biotech AB Interim report January - September 2014

(Thomson Reuters ONE) -


Laquinimod
· Teva presented new clinical safety data in RRMS patients treated with
laquinimod for two or more years at joint ACTRIMS-ECTRIMS meeting
· Teva initiated clinical studies with laquinimod in primary progressive MS
(PPMS) and Huntington's disease
· The ongoing US pivotal clinical study CONCERTO is continuing according to
plan. Results are expected in the first half of 2016

Tasquinimod
· The Phase III study 10TASQ10 is proceeding according to the original schedule
and results are expected in the first half of 2015

ANYARA
· Only out-licensing activities are being conducted

Paquinimod (57-57)
· Only out-licensing activities are being conducted

ISI
· CD selection expected in 2015.

New share issue
· Rights issue totaling approximately SEK 225 million to be approved by the
Extraordinary General Meeting on December 1, 2014

Financial summary

MSEK July - Sept.   January - Sept.   Full Year

  2014 2013   2014 2013   2013
-----------------------------------------------------------------------


Net sales 2.6 107.0   7.5 111.9   116.0



Operating loss -55.7 27.9   -172.8 -128.6   -209.0



Loss for the period -56.6 29.2   -174.5 -130.0   -212.1



Loss per share (SEK) -0.76 0.39   -2.33 -1.77   -2.87

(before and after dilution)



For further information, please contact:

Tomas Leanderson, President and CEO
 Tel: +46 (0)46 19 20 95

Hans Kolam, CFO
Tel: +46 (0)46 19 20 44

Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 00

The report is also available at www.activebiotech.com




Active Biotech AB Interim report January - September 2014 :
http://hugin.info/1002/R/1868647/656843.pdf



This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Active Biotech via GlobeNewswire
[HUG#1868647]

Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 05.11.2014 - 08:30 Uhr
Sprache: Deutsch
News-ID 349791
Anzahl Zeichen: 2792

contact information:
Town:

LUND

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 121 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Active Biotech AB Interim report January - September 2014"
steht unter der journalistisch-redaktionellen Verantwortung von

Active Biotech (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Primary endpoint reached in Active Biotech's TASQ Phase II clinical trial i ...

Lund, Sweden, December 14, 2009 - A first analysis of the primary endpoint based on data from at least six months' treatment of more than 200 patients, has been performed in Active Biotech AB's (NASDAQ OMX Nordic: ACTI) ongoing Phase II cli ...

Active Biotech's election committee appointed ...

In accordance with a decision made by the Annual General Meeting held on May 7, 2009, the Election Committee shall comprise the representatives for the three largest shareholders on September 30 and the Board Chairman. For the 2010 Annual General ...

Active Biotech AB Interim Report, January - September 2009 ...

* Laquinimod -- new data presented at ECTRIMS * 57-57 -- exploratory clinical trial in progress * RhuDex(TM) -- clinical development to continue following feedback from UK MHRA * ANYARA -- complete Phase I data published * TASQ -- complete Phase I ...

Alle Meldungen von Active Biotech